动物造模,慢性酒精性肝损伤大鼠 z-bio 2021-11-04 447

　　Objective: To explore the protection or influence of bifidobacteria (BIFI) on liver function in rats with chronic alcoholic liver injury (chronic alcoholic hepatitis, CALI), and to explore its mechanism of action?

　　 Method: SD rats were randomly divided into CALI group and metadoxines. (90 mg/kg) group, BIFI low (500 mg/kg), medium (1000 mg/kg), high (2000 mg/kg) dose group, sirtuin 1 (Sirt1) inhibitor tenovin -6 (25 mg)/kg) group? Did the CALI group and the blank control group receive the same dose of normal saline gavage? After 8 weeks, analyze the liver function of each group; liver tissue and serum TG to detect TC levels; hematoxylin-eosin (HE) staining to observe the pathological changes of liver tissue; SIRT1 in liver tissue? Western blotting (WB) method to analyze chREBP? expression.

　　Result: Compared with the control group, the liver function of the rats in the CALI group was significantly decreased, and the levels of ALT and AST in the blood were significantly increased. High (P\u003c0.05), liver tissue shows fat pathological damage, TG in liver tissue and serum? The level of TC increased significantly (P\u003c0.05), the expression of SIRT1 protein was significantly reduced (P\u003c0.05), and the expression of chREBP protein was significantly increased (P\u003c0.05). Compared with the CALI group, the liver function of the rats in the CALI group was significantly enhanced at low, medium and high doses of BIFI. In this group, the blood ALT and AST levels were significantly reduced (P \u003cu003c0.05), and the pathological damage of liver tissue was also significantly reduced. The levels of TG and TC in liver tissue and serum were significantly reduced (P\u003c0.05), SIRT1 protein expression was significantly increased (P\u003c0.05), and chREBP protein expression was significantly reduced (P\u003c0.05). Can all of the above effects be specific inhibitors of SIRT1's Tenobin-6 reversal?

　　 Conclusion: Is it possible to inhibit lipid accumulation by regulating the expression of BIFI SIRT1/ChREBP, thereby protecting rats with chronic alcoholic liver injury?